Archived Newsletters

  1. 09.24.26 -- Dr. Heidi Overton And The FDA: An Outsourcing Perspective 9/24/2026
    09/24/26 Outsourced Pharma Newsletter
  2. 09.23.26 -- From Development Strategy To Market Entry 9/23/2026

    09/23/26 Outsourced Pharma Newsletter

  3. 09.23.26 -- FDA Not A Good FRAME for CDMO Inspections? 9/23/2026

    09/23/26 Outsourced Pharma Newsletter

  4. 09.22.26 -- Building Smarter Fill-Finish Operations 9/22/2026
    09/22/26 Outsourced Pharma Newsletter
  5. 09.22.26 -- How Biopharma Is Advancing Precision, Scale, And Speed 9/22/2026

    09/22/26 Outsourced Pharma Newsletter

  6. 09.22.26 -- FDA Not A Good FRAME for CDMO Inspections? 9/22/2026

    09/22/26 Outsourced Pharma Newsletter

  7. 09.21.26 -- Reducing Risk Across The Pharma Supply Chain 9/21/2026

    09/21/26 Outsourced Pharma Newsletter

  8. 09.21.26 -- STREAM New Approaches To Biologics Development 9/21/2026

    09/21/26 Outsourced Pharma Newsletter

  9. 09.21.26 -- FDA Not A Good FRAME For CDMO Inspections? 9/21/2026

    09/21/26 Outsourced Pharma Newsletter

  10. 09.18.26 -- Accelerating Gene Therapy & mRNA Manufacturing 9/18/2026
    09/18/26 Outsourced Pharma Newsletter